VC Survey 2026
“The same sensor fusion and computer vision tech used for military target acquisition are now disrupting surgery”
Amit Alfasi, investor relations manager at Peregrine Ventures, joined CTech for its 2026 VC Survey.
“The most sophisticated disruption is occurring in Healthcare and Surgical Robotics. We are currently witnessing a ‘second wave’ of dual-use innovation. If the first wave brought us optical diagnostics (like PillCam) derived from missile technology, the current wave is adapting battlefield situational awareness and autonomous navigation for the operating room,” said Amit Alfasi, investor relations manager at Peregrine Ventures.
Asked which civilian industry will see the biggest disruption from adapting defense technology, Alfasi explained that 2026 is likely to see a rise in health tech innovations thanks to battle-tested military innovations.
1 View gallery
Amit Alfasi, investor relations manager at Peregrine Ventures.
(Photo: Yossi Zwecker)
“Strategic acquirers explicitly cite Israel’s ‘defense-related medical R&D’ as a distinctive source of value. They recognize that the same sensor fusion and computer vision technologies used for target acquisition are now disrupting surgery, enabling robotic systems to navigate the human anatomy with sub-millimeter precision,” she said.
Following the turbulence of recent years and the stabilization of 2025, the Israeli tech ecosystem is entering a new era: The Next Leap. Alfasi joined CTech to share insights for its VC Survey 2026.
You can read the entire interview below.
Fund ID
Fund Name: Peregrine Ventures
Total Assets Under Management: $600M
Partners/Managers: Eyal Lifschitz, Boaz Lifschitz and Lior Shahory
Notable Portfolio Companies: Insightec, Momentis Surgical, BrainQ, Restore Medical, Cordio Medical, Bioprotect, Kahr
Notable Exits: CartiHeal, Outsence, Endostream, Cardiovalve, Valtech, Eximo
The Global Leap: How is the 'Israeli Tech' asset class being rebranded to global LPs in 2026? Are we shifting the narrative from 'Innovation' to 'Extreme Resilience'?
The narrative shifts from 'Resilience' to 'maturity and proven performance.' While resilience is an inherent trait of the Israeli market, the rebranding for 2026 focuses on quality and consistency. The ecosystem has successfully navigated significant global and local challenges, demonstrating that it possesses the depth and experience to deliver results regardless of market cycles. For global LPs, Israel is now viewed as a highly validated asset class, characterized by experienced management, disciplined capital allocation, and a verified track record of generating real value and innovation under any conditions.
The Deep Tech Leap: With the rising focus on hardware-heavy sectors (Defense, Climate, Quantum), is the Israeli VC model adapted to fund high-CAPEX ventures?
The Israeli ecosystem has developed a unique "lean innovation" model that compensates for the lack of massive, U.S.-style funding rounds. Data consistently shows that Israeli deep-tech companies achieve critical milestones, such as clinical trials or hardware prototyping, with significantly less capital than their global peers. This capital efficiency is the core adaptation, the local model isn't built to deploy more cash, but to require less of it to reach value inflection points. By utilizing a highly multidisciplinary workforce and cost-effective development cycles, the Israeli market proves that high-CAPEX sectors can be viable even with a more disciplined venture capital structure.
The Sovereign Leap: Have the geopolitical lessons of recent years pushed Israeli startups to build independent, 'sovereign' tech stacks to reduce reliance on global platforms?
The lessons of recent years have redefined "sovereignty" in the Israeli tech sector not as isolation, but as ‘business continuity’. In global industries like Healthtech or Semiconductors, complete independence is impossible due to regulatory and supply chain integration. However, the recent logistical challenges have pushed Israeli companies to build operational autonomy, establishing parallel execution infrastructures and remote capabilities to ensure continuous operations. The goal isn't to detach from global platforms, but to ensure that Israeli technology remains a robust, uninterrupted link in the global value chain, capable of delivering reliably regardless of regional instability.
The Next Engine: Cybersecurity has been Israel's primary export engine for a decade. Which domain is best positioned to take the lead by 2030?
Building on the global success of Israel's Cyber and Software sectors, the next economic engine is shifting toward the physical world. Healthtech is poised to lead because it leverages Israel's unique ability to execute complex, multidisciplinary engineering, combining advanced data capabilities with hardware and clinical expertise. This creates tangible, long-term industrial value with high barriers to entry. With global demand for healthcare technologies growing steadily, and Life Sciences already established as a top-tier investment sector in Israel, it is set to become a primary anchor of Israel’s export economy alongside software.
Finally, what are 2-3 startups that, in your opinion, are likely to make a leap forward in 2026?
Biobeat - Following a significant funding round and the strategic strengthening of its leadership team, the company has successfully recalibrated its Go-To-Market strategy. This strategic pivot positions the company to translate its robust monitoring capabilities into accelerated market adoption, expected to yield results this year.
Snipe Medical (Portfolio) - 2026 marks a pivotal milestone for Snipe, with the FDA clearance anticipated this year. Snipe’s system is designed for broad soft-tissue ablation suitable for various solid tumors and has demonstrated a genuine breakthrough in lung cancer treatment, an area with critical unmet needs. With a unique, precise, seamless solution, Snipe is positioning itself as a transformative player in interventional oncology, setting the stage for future mass adoption.
Momentis Surgical (Portfolio) - Positioned for a significant inflection point in 2026 as the company transitions from platform validation to scaled commercialization. With Gen 2 system readiness, expanding FDA-cleared use cases, and initial hospital and Ambulatory Surgery Centers (ASC) deployments, 2026 marks the year where clinical adoption, revenue growth, and strategic optionality converge.
